The North America epilepsy drugs market was valued at USD 4.54 Billion in 2025 and is expected to grow at a CAGR of 5.60%, reaching USD 7.83 Billion by 2035. The market growth is driven by increasing epilepsy prevalence, rising healthcare expenditure, and continued development of novel antiepileptic drugs.
Base Year
Historical Period
Forecast Period
One of the major market trends is the rising entry of generic equivalents of popular epilepsy medications.
The surge in clinical trials to introduce novel epilepsy drugs with better efficacy and minimal side effects is poised to fuel the North America epilepsy drugs market demand.
In the United States, around 3 million people are reported to suffer from epilepsy. The growing number of epilepsy cases coupled with heightened patient awareness is driving the market growth.
Compound Annual Growth Rate
5.6%
Value in USD Billion
2026-2035
*this image is indicative*
Epilepsy is a common neurological condition characterized by recurrent seizures. This chronic noncommunicable disease can occur in people of all ages and is known to affect 50 million individuals worldwide. In the United States, around 3 million people are reported to suffer from epilepsy. The growing number of epilepsy cases coupled with the heightened patient awareness is contributing to the global epilepsy drugs market. Further, it is estimated that 70% of epilepsy patients could live seizure-free following appropriate diagnosis and treatment, indicating the need for effective epilepsy drugs. The rising advancements in drug development supported by the increased research funding and robust government initiatives are expected to drive the North America epilepsy drugs market growth.
Growth in clinical trials to introduce novel epilepsy drugs with better efficacy and minimal side effects is poised to shape the market landscape in coming years. In October 2023, the results of a phase 2b clinical trial of Xenon Pharmaceutical’s (a Canadian neuroscience-focused biopharmaceutical company) investigational drug XEN1101 demonstrated a reduction in seizure frequency by more than 50% in certain epilepsy patients and sometimes even eliminated them altogether. The study, conducted by the researchers at NYU Grossman School of Medicine (a medical school of New York University), also showed that the new oral drug can be started at its most effective dose, unlike other epilepsy treatments that have to be gradually ramped up. Increased clinical trial activities focused on evaluating the clinical outcomes of innovative epilepsy therapeutics is projected to boost the market value in the forecast period.
One of the major North America epilepsy drugs market trends is the rising entry of generic equivalents of popular epilepsy medications. For example, in December 2023, an Indian multinational pharmaceutical company Zydus Lifesciences Limited received US Food and Drug Administration (FDA) approval to manufacture and market a generic version of anti-epileptic medication, Lacosamide Tablets, in multiple strengths. The drug is indicated for the treatment of partial-onset seizures and is also used in combination with other medicines to treat primary generalized tonic-clonic seizures. Since generic medications are generally sold at lower prices than brand-name drugs, this market trend is anticipated to increase the accessibility of essential epilepsy treatment options and thereby augment the market demand.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Seizure Type
Market Breakup by Drug Generation
Market Breakup by Age Group
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
UCB (Union Chimique Belge) is a multinational biopharmaceutical company that specializes in the research and development of epilepsy treatments. In March 2022, the U.S. Food and Drug Administration (FDA) approved its drug (branded as Fintepla) to treat seizures associated with a rare form of childhood epilepsy, Lennox-Gastaut Syndrome (LGS).
This Swiss multinational pharmaceutical corporation's drug asset TRILEPTAL is indicated for monotherapy or adjunctive therapy in adults to treat partial-onset seizures.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City and is actively involved in the development of epilepsy drugs. Its anti-epileptic medication Zarontin (ethosuximide) is used alone or in combination with other medicines to treat absence seizures in adults and children.
The British multinational pharmaceutical and biotechnology company is known for its oral solution Keppra, indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization. It can be taken by adults and adolescents 16 years or above with newly diagnosed epilepsy.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 5.60% during the forecast period of 2026-2035, driven by increased clinical trials and research initiatives to introduce novel anti-epileptic drugs in the region.
Rising healthcare expenditure and heightened patient awareness are fuelling the demand for the market.
One of the market significant trends is the rising entry of generic equivalents of epilepsy medications. For example, in December 2023, United States FDA approved Zydus Lifesciences Limited to manufacture and market a generic version of anti-epileptic medication, Lacosamide Tablets, in multiple strengths.
Based on the seizure type, the market is segmented into focal seizures, generalized seizures, and non-epileptic seizures, among others.
By drug generation, the market is divided into first generation drugs, second generation drugs, and third generation drugs.
By age group, the market is divided into pediatric and adult.
The market breakup by route of administration includes oral, nasal, injectable, and rectal, among others.
Distribution channels of the market are hospital pharmacies, drug stores and retail pharmacies, and online providers.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are UCB SA, Novartis AG, Pfizer Inc., GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Seizure Type |
|
| Breakup by Drug Generation |
|
| Breakup by Age Group |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share